Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

21%); B2 (bronchiolitis obliterans [BO], hypersensitivity pneumonia; 14%) and Bz (unclassified-ILD; 13%). The worst functional status was found among the patients in the Bz category. Corticosteroids ...

Following the death of two-year-old Awaab Ishak, new legislation aims to combat mould and damp issues in homes, protecting ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Wandering to the tree horizon of the Shivaliks entails picking up a thin trail of wild deer that emanates from the heart of the jungle and meanders to a water hole. Walking up the trails that wind ...

The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...

MDedge News, June 06, 2024 ATS 2024 Hypersensitivity Pneumonitis Patients Share Need-to-Knows A survey of adults with hypersensitivity pneumonitis revealed desire for information on prognosis ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

As she and her factory age, production dwindles, and by the time ... Fibrotic hypersensitivity pneumonitis is a chronic and progressive interstitial lung disease, caused by an immune response to ...

This consistent cough and associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant ... adults in the U.S. and is caused by cough reflex ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...